Sanadihii la soo dhaafay, saamaynta isbaarada difaaca ee daawaynta Hodgkin's lymfoma (HL) waa mid cajiib ah, laakiin cudurku wali wuxuu u baahan yahay in si fiican looga gudbo. Gudoomiyaha Kooxda Lymphoma ee Mayo Clinic Ansell sai..
Cilmi-baarayaal ka tirsan Jaamacadda California, San Francisco iyo St. Jude Children's Hospital ee Tennessee ayaa xalliyay siraha caafimaadka tobannaan sano ka hor, waxayna heleen lammaane isbeddellada hidde-raaca ah oo sababi kara faw.
FDA waxay siisay daawadeeda horumarsan ee quizartinib daawaynta horumarsan. Quizartinib waa FLT3 inhibitor oo hoos yimaada baaritaanka daaweynta bukaanada qaangaarka ah ee soo noqnoqday / dib u soo noqday FLT3-ITD myeloi ba'an.
Maamulka Cuntada iyo Dawooyinka ee Mareykanka ayaa ansixiyay Venetoclax (Venclexta) oo ay weheliso rituximab (VenR) ee daaweynta bukaannada qaba leukemia dabadheeraad ah (CLL) oo ku saleysan xogta cudurka haraaga ugu yar (MRD) ee wajiga.
Sida laga soo xigtay tijaabo caafimaad oo xarumo badan leh oo ay hogaaminayaan cilmi-baarayaal ka tirsan Jaamacadda Stanford School of Medicine, nooc cusub oo immunotherapy ah ayaa u muuqda mid badbaado u ah bukaannada qaba kansarka dhiigga ee loo yaqaanno non-Hodgkin's lymphoma. The therapy com.
Marka loo eego natiijooyinka wejiga labaad ee daraasadda, isku dhafka daryeelka caadiga ah ee daaweynta kemotherabi daawada azacitidine iyo isbaarada isbaarada difaaca ee nivolumab (nivolumab) ayaa muujisay in heerka jawaabta iyo soo noqoshada.
On November 28, FDA approved the first rituximab (Rituxan, rituximab) biosimilar, Truxima (rituximab-abbs, Celltrion Inc.) for non-Hodgkin's lymphoma (NHL). Rituximab is a monoclonal antibody against CD20. It is widely used..
FDA waxay ogolaatay gilteritinib (Xospata) ee loogu talagalay daaweynta bukaanada qaangaarka ah ee leh FLT3 mutation-positive soo noqoshada ama leukemia ba'an ee myeloid (AML). Marka loo isticmaalo gil..
Natiijooyinka tijaabooyinka bukaan-socodka ee wajiga III ee dhexdhexaadka ah waxay muujiyeen in haddii bukaannada waayeelka ah ee qaba kansarka leukemia ee daba-dheeraada (CLL) lagu daaweeyo dawo cusub oo lala beegsaday ibrutinib marka la barbar dhigo commo hore.
Venetoclax (Venclexta) iyo rituximab (Rituxan) ayaa loo isticmaalaa marka lagu daro soo noqnoqoshada / refractory lymphocytic leukemia (CLL), taasoo keentay heer sare oo aan la ogaan karin ugu yar ee cudur haraaga ah (uMRD), taas oo ah sida ...